Project governance

Governing bodies

The Executive Steering Committee (ESC) is common to Ebola+ projects in which Janssen is participating and makes high-level decisions with regards to these Ebola+ projects. The ESC will be chaired by Crucell Holland B.V, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen).


The Clinical Steering Committee (CSC) is common to EBOVAC1 and EBOVAC2 projects and makes high-level decisions and approvals regarding implementation strategies and dispute resolution for issues arising from the Management Committee (MC). Issues that cannot be resolved by the CSC will be escalated to the ESC. The CSC will be chaired by Janssen.

The EBOVAC2 Management Committee (MC) is in charge of the overall steering (contractual, clinical and scientific) of the project in line with the decisions made by the Clinical Steering Committee, the Executive Steering Committee and the advice provided by the External Advisory Groups. The EBOVAC2 MC will be chaired by Inserm.

Independent advisory boards

Scientific Advisory Boards

The Scientific Advisory Board (SAB) is a consultative body composed of independent inter-disciplinary scientific experts whose role is to provide scientific advice to all projects funded under the Ebola+ programme to ensure maximum impact in scientific, technological and health terms for all concerned parties. The SAB will, where and when relevant, review project deliverables, advise on scientific and technologic choices and for this purpose attend key project events. The SAB will be set up and managed by Inserm with the support of Inserm Transfert (EBOVAC2).

Ethics Board

The Ethics board will have a consultative role in the project and be asked, where and when relevant, to attend project meetings. The final list of sites, the final study protocol, approbation of Ethics Board, and clinical trial registration number will always be provided to IMI2JU. The Ethics Boards will be set up managed by LSHTM (EBOVAC1).

News

  • 15 May 2017

    Based on final Phase 1 data published in JAMA: The Journal of the American Medical Association, the prime-boost Ebola vaccine regimen induced an antibody response that persisted in 100 percent of healthy volunteers to at least 1 year following vaccination. The results are from the EBOVAC1 study EBL1001 conducted by the Oxford Vaccine Group in the UK.

  • 15 May 2017

    Victoria Derbyshire reporter Catrin Nye went to visit the Oxford Vaccine Group looking for volunteers who participated in the EBL2001 study. Prof. Andrew Pollard (Professor of Paediatric Infection and Immunity and Oxford Vaccine Group PI for EBOVAC1 and EBOVAC2 ) and study volunteers were interviewed.Watch here : http://www.bbc.co.uk/news/uk-39202974

  • 13 November 2016

    The joint EBOVAC1 and EBOVAC2 annual meeting took place in Windsor, UK from 14-16 November 2016.

  • 22 April 2016

    EBOVAC1 has published their first report on Phase 1 data in the April 19th 2016 issue of JAMA

    Press release and more information

  • 04 April 2016

    The first subject was vaccinated on 30 March 2016 at the University of Nairobi, Kenya

  • 29 March 2016

    The 1st EBOVAC2 Newsletter is available!

More news
  • Ebola: background

    What is Ebola?

  • Phase 2 trials

    Find out more about EBOVAC2 trials

  • Work programme

    EBOVAC2 is organised into 6 workpackages (WP)

  • Ebola+ programme

    Contributes to efforts to tackle a wide range of challenges in Ebola research